Dyslipidaemia and cytokine profile in patients with gout: the role of il-6, il-18 and hyperuricemia in the development of metabolic disorders

Abstract

Evaluation of the correlation of immunological and biochemical values with clinical manifestations of gout, as well as the role of hyperuricemia in comorbid states is an important for the search of therapeutic targets. Objective: Investigation of the relationship between features of dyslipidaemia and immunological changes in patients with tophaceous gout and asymptomatic hyperuricemia. Patients and Methods: The study has included 85 male patients: 1st (main) group – 49 patients with primary chronic gout according to criteria of Wallace S.L., 2nd (control) group – 36 patients with asymptomatic hyperuricemia. The levels of uric acid (UA), C-reactive protein (CRP), fasting glycaemia, lipid profile – total cholesterol (TC), triglycerides (TG), high-density (HDL), low density (LDL), very low density (VLDL) lipoproteins, atherogenic ratio (AR); concentrations of cytokine: interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-α), IL-4, IL-6, IL-8, IL-10 and IL-18 in the blood serum by enzyme-linked immunosorbent analysis. Results: Values of UA have positively correlated with the number of affected joints (r=0.64, p=0.058), presence of tophi (r=0.73, p=0.042), glycaemic level (r=0.74; p=0.038). An increase of TC to 11.85%, LDL to 22.51%, VLDL to 21.43% and a decrease of HDL to 20.9% in patients with gout was observed. AR was higher in the group of patients with gout to 25.8% (p=0.0088).